New Zealand healthcare shops bcg2 Health and Spitfire win Pfizer Australia’s haemophilia pitch

| | No Comments

xyntha.jpgAuckland-based bcg2 Health and Spitfire have won Pfizer Australia’s haemophilia treatments pitch.

The two agencies worked together to provide a perfect blend of specialist healthcare knowledge and communication skills combined with specialist digital strategy and production.

 

The Pfizer Australia pitch was for Xyntha and BeneFIX, two brands used in the treatment of haemophilia. The win against two Australian agencies means bcg2 Health now has the business on both sides of the Tasman after a successful Pfizer New Zealand pitch in November 2010.

benefix.jpgSays Stuart Ogden, general manager of bcg2 Health: “It’s great to gain even more traction in this market on the strengths of our efforts in New Zealand, as we further establish ourselves as healthcare communication specialists across the Tasman.”

 

John Madden, creative director from Spitfire comments: “We see the healthcare markets really embracing digital technology. It allows us to connect healthcare professionals with their patients in ways that add value to the relationship and feels intuitive to users. Working closely with the bcg2 Health team is proving to be incredibly valuable”.

 

Over the past seven months, bcg2 Health has pitched and won two other campaigns from Pfizer’s New Zealand Speciality Care Division. The first is a campaign for Prevenar 13, an infant vaccine for pneumococcal disease. The second is Enbrel, used to treat Rheumatoid Arthritis and Psoriasis. Both of these wins were in addition to being awarded Pfizer’s Avigra® in April.    

 

In addition to these new business wins, bcg2 Health has hired a specialist healthcare Group account director Helen Purcell. Helen is a recent arrival from New York, where she worked in the pharmaceutical communications area for the previous sixteen years at leading agencies like Y&R, Ogilvy and Grey. With prior experience working on Pfizer brands in the USA Purcell will be responsible for Pfizer New Zealand business and the haemophilia portfolio in Australia.